Testing TQB3002 in patients with advanced cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase I clinical trial evaluates the safety, tolerability, and efficacy of TQB3002 tablets in patients diagnosed with advanced cancers. Participants must have advanced malignancies that have not responded to standard therapies or for which no effective treatment options are available. The study aims to determine how well TQB3002 can be tolerated and its potential effectiveness in this patient population. Eligible participants are those aged 18-75 with a good performance status and expected survival of more than three months.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects voluntarily joined this study, signed the informed consent form, and had good compliance；
* Age: ≥ 18 years old; Eastern Cooperative Oncology Group (ECOG) score: 0-1 ; Expected survival of more than 3 months；
* Histologically or cytologically diagnosed with advanced cancers
* Subjects with advanced malignancies who have failed standard therapy or lack effective treatment
* Major organs are functioning well；
* Female and male subjects of childbearing potential should agree to practice contraception for the duration of the study and for 6 months after the end of the study.

Exclusion Criteria:

* Current concomitant presence of other malignancies within 5 years prior to the first dose；
* Unresolved toxicity above CTCAE Grade 1 due to any prior anti-tumor therapy
* Significant surgical treatment, biopsy, or significant traumatic injury within 4 weeks prior to the first dose
* Long-term unhealed wounds or fractures
* Cerebrovascular accident (including transient ischemic attack, intracerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism within 6 months prior to the first dose
* Swallowing dysfunction, active gastrointestinal diseases or other diseases that significantly affect the absorption, distribution, metabolism and excretion of the study drug, or previous subtotal gastrectomy
* A history of psychotropic drug abuse and cannot be abstained from or have a mental disorder
* Subjects with any severe and/or uncontrolled disease

Where it's running

• Guangdong Provincial People's Hospital
  Guangzhou, Guangdong, China Recruiting
• Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
  Shenzhen, Guangdong, China Not yet recruiting
• Henan Cancer Hospital
  Zhengzhou, Henan, China Not yet recruiting
• Jiangsu Province Hospital
  Nanjing, Jiangsu, China Not yet recruiting
• The First Affiliated Hospital Of Nanchang University
  Nanchang, Jiangxi, China Not yet recruiting
• Shanghai Pulmonary Hospital
  Shanghai, Shanghai Municipality, China Not yet recruiting

Study contacts

• Study coordinator: Qing Zhou, Doctor
• Email: zhouqing@gdph.org.cn
• Phone: 020-83827812

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Concise coaching to guide decisions for advanced cancer patients considering palliative procedures

  A coaching program delivered by lay providers will test whether it helps adults with advanced cancer make better, patient-aligned decisions about palliative surgeries or similar interventions.

  Recruiting Singapore General Hospital · Singapore · NCT07789093

• Primary Palliative Care: A Feasibility Project for Family Health Units

  This feasibility trial tests a GP training program plus a structured 12-week palliative-care visit plan to see if it can be carried out in primary care for adults with advanced illness.

  Recruiting University of Coimbra · Coimbra and 1 other locations · NCT07737899

• Virtual Group Resilient Living for Advanced Cancer

  A group-based online program tests whether seven weekly sessions can reduce anxiety and fatigue and improve quality of life for adults with advanced cancer.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07659158

• IV contrast-enhanced CBCT with HyperSight for image guidance in advanced cancer radiotherapy

  This study tests whether giving IV contrast during cone-beam CT helps doctors see the tumor better during radiotherapy in people with advanced cancer.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07648160

• Single-session celiac plexus SBRT using a simulation-free adaptive workflow for cancer-related pain

  A pilot test to see if a one-day, simulation-free adaptive radiotherapy process can safely deliver celiac plexus SBRT to adults with advanced pancreatic or other cancers.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07636382

• UI-102 in advanced cancers (phase 1/2) first-in-human

  A first-in-human study tests UI-102, given to adults with advanced solid tumors to see if it is safe and shows signs of benefit.

  Recruiting at 3 sites Phase 1/2 United Immunity, co., Ltd. · Dallas, Texas and 2 other locations · NCT07605962

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.